CEL-SCI Corporation (NYSE American: CVM) announced the closing of its best-efforts public offering of 6 million shares of common stock at $1.20 per share, generating gross proceeds of approximately $7.2 million before fees and expenses. The company stated that net proceeds will be used to support the continued development of Multikine, its lead investigational immunotherapy, as well as for general corporate purposes and working capital.
Multikine (Leukocyte Interleukin, Injection) is designed to boost a patient's immune system before surgery, radiotherapy, and chemotherapy have damaged it, aiming to provide the greatest possible impact on survival. The therapy is intended to help the immune system “target” the tumor at a time when the immune system is still relatively intact, thereby mounting a more effective attack on the tumor. Multikine has been dosed in over 740 patients and has received Orphan Drug designation from the U.S. Food and Drug Administration for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
The successful capital raise comes at a critical time for CEL-SCI as it advances Multikine through clinical development. The company believes that intervening with immunotherapy before standard treatments may improve patient outcomes. The additional funding will enable CEL-SCI to continue clinical trials and prepare for potential regulatory submissions.
For business and technology leaders, this development underscores the growing focus on immunotherapies that harness the body's immune system to fight cancer. The ability to raise capital in a challenging market environment signals investor confidence in CEL-SCI's approach and the potential of Multikine. If successful, Multikine could represent a paradigm shift in the treatment of head and neck cancer, offering a new option for patients before traditional therapies.
The company operates from facilities in Vienna, Virginia, and near Baltimore, Maryland. For more information about CEL-SCI and Multikine, visit https://cel-sci.com/. The full press release is available at https://ibn.fm/T5Ng2.
